4-[2-[1-oxo-1,2-dihydrophthalazin-2-yl]ethoxy]benzaldehyde | 214282-14-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-[2-[1-oxo-1,2-dihydrophthalazin-2-yl]ethoxy]benzaldehyde
• 英文别名: 4-[2-[1-oxo-1,2-dihydro-phthalazin-2-yl]ethoxy]benzaldehyde；4-[2-(1-oxo-1,2-dihydrophthalazin-2-yl)ethoxy]benzaldehyde；4-[2-[1-oxo-2(1H)-phthalazinyl]ethoxy]benzaldehyde；4-[2-(1-oxophthalazin-2-yl)ethoxy]benzaldehyde
• CAS: 214282-14-1
• 化学式: C₁₇H₁₄N₂O₃
• 分子量: 294.31
• InChiKey: ULYBILPYIXUAES-UHFFFAOYSA-N

物化性质

• 沸点：
  524.9±56.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[2-[1-oxo-1,2-dihydrophthalazin-2-yl]ethoxy]benzaldehyde 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.5h， 以92%的产率得到4-[2-[1-oxo-2(1H)-phthalazinyl]ethoxy]benzyl alcohol
  参考文献：
  名称：

  5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY

  摘要：

  公开号：

  EP1228067B1
• 作为产物：
  描述：

  2-(4-formylphenoxy)ethyl methanesulfonate 、 1-(2H)-酞嗪酮 在 potassium carbonate 作用下， 以 N-甲基乙酰胺 为溶剂， 生成 4-[2-[1-oxo-1,2-dihydrophthalazin-2-yl]ethoxy]benzaldehyde
  参考文献：
  名称：

  Alpha-Substituted phenylpropionic acid derivative and medicine containing the same

  摘要：

  公开号：

  EP0903343B1

文献信息

• Heterocyclic compounds having antidiabetic hypolipidemic
  申请人：Dr. Reddy's Research Foundation

  公开号：US06011036A1

  公开（公告）日：2000-01-04

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their analogues, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione compounds of the general formula (I), and their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物，它们的互变异构体、类似物、衍生物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮化合物及其类似物、衍生物、互变异构体、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用组合物。
• 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07179823B1

  公开（公告）日：2007-02-20

  A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: —CO—, —CS—, —CR4(OR5)— or —NR6— wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: —SO—, —SO2—, —NR7—, —CONR7— or —NR7CO— wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.

  化合物的式子为（I）F，其中R1代表一个可以被取代的碳氢基团或杂环基团；x代表一个键、一个氧原子、一个硫原子或者一个式子为：—CO—、—CS—、—CR4(OR5)—或—NR6—的基团，其中R4和R6分别代表一个氢原子或者一个可以被取代的碳氢基团，R5代表一个氢原子或者一个羟基的保护基团；m代表一个0到3的整数；Y代表一个氧原子、一个硫原子或者一个式子为：—SO—、—SO2—、—NR7—、—CONR7—或—NR7CO—的基团，其中R7代表一个氢原子或者一个可以被取代的碳氢基团；环A代表一个芳香环，可以有1到3个取代基；n代表一个1到8的整数；环B代表一个含氮的5元杂环，可以有一个烷基的取代基。
• 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1457490A1

  公开（公告）日：2004-09-15

  Use of a compound of the formula: wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR4(OR5)- or -NR6- wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be substituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -NR7-, -CONR7- or -NR7CO- wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X1 represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -O-SO2- or -NR16- wherein R16 represents a hydrogen atom or a hydrocarbon group which may be substituted; R2 represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R3 represents a group of the formula: -OR8 (R8 represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR9R10 (each of R9 and R10, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R9 and R10 may bind together to form a ring); or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating syndrome X.

  式化合物的用途： 其中 R1 代表可被取代的烃基或可被取代的杂环基； X 代表键、氧原子、硫原子或式中的基团：-其中 R4 和 R6 分别代表氢原子或可被取代的烃基，R5 代表氢原子或羟基的保护基团； m 代表 0 至 3 的整数； Y 代表氧原子、硫原子或式中的一个基团：-其中 R7 代表氢原子或可被取代的烃基； 环 A 代表芳香环，可进一步具有 1 至 3 个取代基； n 代表 1 至 8 的整数； 环 B 代表含氮 5 元杂环，可进一步被烷基取代； X1 代表键、氧原子、硫原子或式中的基团：-其中 R16 代表氢原子或可被取代的烃基； R2 代表氢原子、可被取代的烃基或可被取代的杂环基； W 代表键或具有 1 至 20 个碳原子的二价烃残基； R3 代表式中的一个基团：-OR8(R8代表氢原子或可被取代的烃基)或-NR9R10(R9和R10，无论是否相同，各自代表氢原子、可被取代的烃基、可被取代的杂环基或可被取代的酰基；R9和R10可结合在一起形成环)；或其盐、 用于制造预防或治疗 X 综合征的药物制剂。
• Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents
  作者：Gurram R Madhavan、Ranjan Chakrabarti、Sunil K.B Kumar、Parimal Misra、Rao N.V.S Mamidi、V Balraju、Katneni Kasiram、Ravi K Babu、Juluri Suresh、Braj B Lohray

  DOI：10.1016/s0223-5234(01)01257-0

  日期：2001.8

  We report here the synthesis of a series of 5-[4-[2-[substituted phthalazinones-2(or 4)yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and 5-[4-[2-[2,3-benzoxazine-4-one-2-yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and their plasma glucose and plasma triglyceride lowering activity in db/db mice. In vitro PPAR gamma transactivation assay was performed in HEK 293T cells. In vitro and in vivo pharmacological studies showed that the phthalazinone analogue has better activity. PHT46 (compound 5a), the best compound in this series, showed better in vitro PPAR gamma transactivation potential than troglitazone and pioglitazone. In insulin resistant db/db mice, PHT46 showed better plasma glucose and triglyceride lowering activity than the standard drugs. Pharmacokinetic study in Wistar rats showed good systemic exposure of PHT46. Subchronic toxicity study in Wistar rats did not show any treatment-related adverse effect. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
• THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES HAVING ANTIDIABETIC, HYPOLIPIDAEMIC AND ANTIHYPERTENSIVE PROPERTIES
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0971917A1

  公开（公告）日：2000-01-19